Waldencast plc (WALD)
NASDAQ: WALD · Real-Time Price · USD
3.550
-0.050 (-1.39%)
Oct 3, 2024, 3:54 PM EDT - Market closed

Company Description

Waldencast plc operates in the beauty and wellness industry.

It engages in developing, acquiring, accelerating, and scaling various brands. The company provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.

It also offers clean makeup products under the Milk Makeup brand. The company sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.

Waldencast plc was incorporated in 2020 and is headquartered in White Plains, New York.

Waldencast plc
Waldencast logo
Country United States
Founded 1988
IPO Date Mar 16, 2021
Industry Shell Companies
Sector Financials
Employees 284
CEO Michel Brousset

Contact Details

Address:
10 Bank Street, Suite 560
White Plains, New York 10606
United States
Phone 917 546 6828
Website waldencast.com

Stock Details

Ticker Symbol WALD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001840199
CUSIP Number G9503X103
ISIN Number JE00BPG99318
SIC Code 2844

Key Executives

Name Position
Michel Brousset Founder, Chief Executive Officer and Director
Hind Sebti Founder and Chief Growth Officer
Manuel Manfredi Chief Financial Officer
Elisabeth Milan General Counsel

Latest SEC Filings

Date Type Title
Aug 30, 2024 144 Filing
Aug 28, 2024 6-K Report of foreign issuer
Aug 27, 2024 6-K Report of foreign issuer
Aug 27, 2024 6-K Report of foreign issuer
Aug 21, 2024 6-K Report of foreign issuer
Jul 8, 2024 424B3 Prospectus
Jul 5, 2024 EFFECT Notice of Effectiveness
Jul 2, 2024 UPLOAD Filing
Jun 27, 2024 6-K Report of foreign issuer
Jun 26, 2024 F-3 Filing